Nobel Prize in Medicine for immune system guardians

Two Americans and one Japanese scientist honored for revolutionary discoveries on the balance of the immune system in autoimmune diseases

07-Oct-2025
© The Nobel Committee for Physiology or Medicine. Ill. Mattias Karlén

The Nobel Prize in Physiology or Medicine 2025

The Nobel Assembly at Karolinska Institutet has decided to award the 2025 Nobel Prize in Physiology or Medicine to: Mary E. Brunkow (Institute for Systems Biology, Seattle, USA), Fred Ramsdell (Sonoma Biotherapeutics, San Francisco, USA) ans Shimon Sakaguchi (Osaka University, Osaka, Japan) “for their discoveries concerning peripheral immune tolerance”.

They discovered how the immune system is kept in check

The body’s powerful immune system must be regulated, or it may attack our own organs. Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi are awarded the Nobel Prize in Physiology or Medicine 2025 for their groundbreaking discoveries concerning peripheral immune tolerance that prevents the immune system from harming the body.

Every day, our immune system protects us from thousands of different microbes trying to invade our bodies. These all have different appearances, and many have developed similarities with human cells as a form of camouflage. So how does the immune system determine what it should attack and what it should defend?

Mary Brunkow, Fred Ramsdell and Shimon Sakaguchi are awarded the Nobel Prize in Physiology or Medicine 2025 for their fundamental discoveries relating to peripheral immune tolerance. The laureates identified the immune system’s security guards, regulatory T cells, which prevent immune cells from attacking our own body.

“Their discoveries have been decisive for our understanding of how the immune system functions and why we do not all develop serious autoimmune diseases,” says Olle Kämpe, chair of the Nobel Committee.

Shimon Sakaguchi was swimming against the tide in 1995, when he made the first key discovery. At the time, many researchers were convinced that immune tolerance only developed due to potentially harmful immune cells being eliminated in the thymus, through a process called central tolerance. Sakaguchi showed that the immune system is more complex and discovered a previously unknown class of immune cells, which protect the body from autoimmune diseases.

Mary Brunkow and Fred Ramsdell made the other key discovery in 2001, when they presented the explanation for why a specific mouse strain was particularly vulnerable to autoimmune diseases. They had discovered that the mice have a mutation in a gene that they named Foxp3. They also showed that mutations in the human equivalent of this gene cause a serious autoimmune disease, IPEX.

Two years after this, Shimon Sakaguchi was able to link these discoveries. He proved that the Foxp3 gene governs the development of the cells he identified in 1995. These cells, now known as regulatory T cells, monitor other immune cells and ensure that our immune system tolerates our own tissues.

The laureates’ discoveries launched the field of peripheral tolerance, spurring the development of medical treatments for cancer and autoimmune diseases. This may also lead to more successful transplantations. Several of these treatments are now undergoing clinical trials.

Other news from the department science

Most read news

More news from our other portals

Last viewed contents

GEA Supervisory Board takes early decision to extend contract of CEO Stefan Klebert - Company resolves to restructure the Executive Board and streamline the organizational structure as of January 1, 2026

GEA Supervisory Board takes early decision to extend contract of CEO Stefan Klebert - Company resolves to restructure the Executive Board and streamline the organizational structure as of January 1, 2026

Mosaic Therapeutics appoints Thomas Fuchs as CEO - Former CEO of Cimeio Therapeutics, and Global Haematology Franchise Head at Roche-Genentech, brings extensive track record of strategic and operational leadership

Mosaic Therapeutics appoints Thomas Fuchs as CEO - Former CEO of Cimeio Therapeutics, and Global Haematology Franchise Head at Roche-Genentech, brings extensive track record of strategic and operational leadership

WIKA strengthens management team with Axel Schwerdtfeger - Process Solutions company division under new leadership

WIKA strengthens management team with Axel Schwerdtfeger - Process Solutions company division under new leadership

Otto Warburg Medal 2026 awarded to Maya Schuldiner

Otto Warburg Medal 2026 awarded to Maya Schuldiner

Research on rewiring neural circuit in fruit flies wins 2025 Eppendorf & Science Prize

Research on rewiring neural circuit in fruit flies wins 2025 Eppendorf & Science Prize

Insilico Medicine-led study combines quantum computing and generative AI for drug discovery - “Quantum computing is recognized as the next technology breakthrough which will make a great impact, and the pharmaceutical industry is believed to be among the first wave of industries benefiting from the advancement”

Insilico Medicine-led study combines quantum computing and generative AI for drug discovery - “Quantum computing is recognized as the next technology breakthrough which will make a great impact, and the pharmaceutical industry is believed to be among the first wave of industries benefiting from the advancement”

Waters Corporation and Princeton University Announce Multi-Year Research Collaboration - Agreement to take on real-world challenges in biologics and materials research

Waters Corporation and Princeton University Announce Multi-Year Research Collaboration - Agreement to take on real-world challenges in biologics and materials research

New biotech venture PHIOGEN to tackle the global threat of antimicrobial resistance - By optimizing nature’s defenders, the team has produced unprecedented phage treatments

New biotech venture PHIOGEN to tackle the global threat of antimicrobial resistance - By optimizing nature’s defenders, the team has produced unprecedented phage treatments

CureVac and MD Anderson enter strategic collaboration to develop novel cancer vaccines - Collaboration aims to develop novel, off-the-shelf, mRNA-based cancer vaccines in selected hematological and solid cancers with high unmet medical need

CureVac and MD Anderson enter strategic collaboration to develop novel cancer vaccines - Collaboration aims to develop novel, off-the-shelf, mRNA-based cancer vaccines in selected hematological and solid cancers with high unmet medical need

First-of-its-kind vaccine expands malaria protection for pregnant women - Sanaria® PfSPZ Vaccine protects women against malaria before and during pregnancy for at least two years

First-of-its-kind vaccine expands malaria protection for pregnant women - Sanaria® PfSPZ Vaccine protects women against malaria before and during pregnancy for at least two years

Bayer awards incubator opportunity to Genvor - Critical resources will help Genvor to grow and scale biological crop protection products and innovative trait technologies

Bayer awards incubator opportunity to Genvor - Critical resources will help Genvor to grow and scale biological crop protection products and innovative trait technologies

Merck and Washington University in St. Louis Sign MoU to Advance Scientific Collaboration - Strategic academic-industry alliance aims to build robust Research & Development talent pipeline

Merck and Washington University in St. Louis Sign MoU to Advance Scientific Collaboration - Strategic academic-industry alliance aims to build robust Research & Development talent pipeline